Meningitis B Vaccines For High-Risk Groups Only: ACIP unanimous vote - Outbreak News Today | Outbreak News Today Outbreak News Today
Subscribe: RSS Twitter

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) unanimously voted today in favor of recommending meningococcal group B vaccines, including the Novartis vaccine, Bexsero®, for use to vaccinate high-risk groups in the US, such as individuals with immune-deficiencies and use of vaccines during outbreaks.

Meningococcal meningitis survivor and vaccination advocate Leslie Meigs looks on as her brother Andrew (18), a college student in Texas, receives Bexsero®, a meningococcal group B vaccine approved by the FDA for ages 10-25 in January. Meningococcal group B is one of the most prevalent types of meningococcal disease in the US, and adolescents and young adults are at risk due to common lifestyle habits such as living in college dormitories. Bexsero is approved to help protect against the potentially deadly disease in two doses, however is not expected to cover all group B strains.

Meningococcal meningitis survivor and vaccination advocate Leslie Meigs looks on as her brother Andrew (18), a college student in Texas, receives Bexsero®, a meningococcal group B vaccine approved by the FDA for ages 10-25 in January. Meningococcal group B is one of the most prevalent types of meningococcal disease in the US, and adolescents and young adults are at risk due to common lifestyle habits such as living in college dormitories. Bexsero is approved to help protect against the potentially deadly disease in two doses, however is not expected to cover all group B strains.

While this is a step forward in addressing Neisseria meningitidis group B (also known as MenB), one of the most prevalent serogroups of meningococcal disease in the US, it still leaves many college students and adolescents at risk for contracting the disease for the foreseeable future.

“Today’s high-risk recommendation does not cover the majority of adolescents and young adults in the US, who are at risk for contracting MenB. The MenB cases in recent weeks at Providence College, University of Oregon and Yale University all serve as a sobering reminder of the importance to act before additional individuals contract this potentially life-threatening disease,” said Andrin Oswald, Division Head, Novartis Vaccines, “We hope that ACIP will soon include MenB vaccines in a broader recommendation to help ensure everyone in this age range is aware of and has access to the vaccine.”

Thus, it is vitally important that the conversation broached today of providing a broader recommendation for the use of MenB vaccines continues, to encourage a vote for broader vaccination at the next ACIP meeting in June. Many colleges already require students to get the meningitis A, C, W, Y vaccine, but MenB is not yet required. Bexsero is currently available to protect adolescents across the country from MenB– the photo included below depicts the brother of meningitis survivor and advocate Leslie Meigs, one of the first teenagers in the US to receive the vaccine.

Related: Meningitis Angels and the ‘Cost of measles’

Passport 1

2 Comments

  1. […] Novartis criticized as too narrow.Use New Meningitis Vaccines Sparingly, Panel AdvisesNBCNews.comMeningitis B Vaccines For High-Risk Groups Only: ACIP unanimous voteOutbreak News TodayPfizer, Novartis get MenB ACIP nod–but not the one they're really […]

  2. […] response to the decision earlier this week by the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization […]

Leave a Reply

© 2016 Outbreak News Today · Subscribe: RSS Twitter ·